Chirag A. Shah, MD, presents and reviews the case of a 59-year-old woman with ovarian cancer.
A 59-Year-Old Woman with Ovarian Cancer
A gynecologic oncologist discusses the importance of molecular testing in ovarian cancer and how it influences treatment selection.
Dr Chirag A. Shah explains the front-line treatment options for ovarian cancer and the factors considered in choosing maintenance therapies.
An expert shares data from several clinical trials on the use of PARP inhibitors for maintenance therapies in ovarian cancer.
Chirag A. Shah, MD, details his personal clinical experience with using niraparib for ovarian cancer maintenance therapies.
Dr Chirag A. Shah highlights novel emerging treatments in ovarian cancer and provides advice for community oncologists.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
